Legend Biotech Corp. - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים LEGN

Legend Biotech is implementing automated cell processing systems to eliminate contamination of biological products. The year-over-year sales trajectory (TTM) visualizes this process, where 50.60 characterizes this valuation parameter. The success of Carvykti and the alliance with J&J establish a foundation for stable cash flow, although regulatory complexities and new product launch costs remain key risks.

This metric measures the percentage change in revenue over the last twelve months, neutralizing seasonality and reflecting the actual pace of business expansion. For Legend Biotech (LEGN), this growth confirms the commercial success of its innovative cell therapy and the efficiency of its partner distribution. Analyzing the TTM revenue YoY dynamics allows for the separation of systemic scaling from random sales spikes. Fundamentally, this metric serves as an indicator of the company's stability, requiring a comparison with the debt load to assess risks.